Incyte, Penn's Abramson Cancer Center partner on study

Incyte Corp. will conduct a multi-year research project in conjunction with the Abramson Cancer Center at the University of Pennsylvania aimed at advancing the understanding of cancer biology.
Incyte will provide financial support for Penn’s research programs, while Penn’s investigators will use knowledge and expertise in preclinical biology to research Incyte’s novel therapeutics to assess their mechanisms of action.
The goal of the collaboration will be to better define the relationships between human tumor characteristics and immune cell infiltration and function.
“Incyte and Abramson are mutually committed to the advancement of science and improving the lives of patients with cancer. This alliance will allow us to mobilize two groups of leading scientists toward the collective goal of advancing the field of immunotherapy,” Incyte Chief Scientific Officer Reid Huber said. “We are excited for the opportunity to partner with the world-class researchers at Abramson and investigate new avenues for the treatment of patients with cancer.”
Incyte is a biopharmaceutical company headquartered in Delaware that focuses on discovering and commercializing proprietary therapeutics.